Valeant’s Acquires Medicis & Could Dominate The US Dermatology Market – ValueWalk Premium
Valeant Pharmaceuticals earnings

Valeant’s Acquires Medicis & Could Dominate The US Dermatology Market

Valeant Pharmaceuticals Int (NYSE:VRX) (TSE:VRX) announced on Labor Day, a deal to acquire Medicis Pharmaceutical Corp (NYSE:MRX) in a $2.6 billion deal.

The Medicis shareholders would be paid $44 in cash per share held, marking a premium of 39% over the closing price of their stock on Friday.

Medicis Pharmaceutical Corp (NYSE:MRX) was the market leader in dermatology . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk

The top investors are reading ValuewalkPremium.

Click here to learn why

0